Compare AbbVie Inc (ABBV) vs Iron Mountain Inc (IRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Iron Mountain Inc — how do they compare? AbbVie Inc trades at $252.95 (market cap $449.91B), while Iron Mountain Inc trades at $116.79 (market cap $34.44B). The key difference: AbbVie Inc is far larger — about 13.1× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals.
| ABBV | IRM | |
|---|---|---|
Market Cap | $449.91B | $34.44B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $133.06 |
52-Week Low | $184.85 | $78.86 |
Enterprise Value | $513.38B | $53.57B |
Dividend Yield | 2.72% | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $251.81, down 1.16% on the day, with strong analyst support showing 68% buy ratings and a $266.33 consensus price target. The stock exhibits bullish technical momentum with recent earnings beats in Q3 2025 through Q1 2026, though Q2 2026 expectations are set at $3.79 EPS. Revenue growth remains solid with 2025 reaching $61.16B, while profitability metrics show a 70.68% gross margin offset by a thinner 5.79% net margin. Recent news highlights pipeline strength with positive Phase 2 ovarian cancer data and institutional accumulation.
The outlook for ABBV is positive driven by robust immunology drugs Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s present long-term risks. Current valuation multiples appear elevated with P/E at 124.83 and P/B at 245.29, requiring sustained execution to justify premiums. Dividend reliability with recent $1.73 payments supports income investors, while technical resistance near $259-266 may cap near-term gains.
Iron Mountain (IRM) trades at $115.75, down 1.2% on the day, with strong recent earnings beats and a bullish analyst consensus of $138.67 price target. The stock shows technical bearish signals despite positive momentum news, while fundamentals reveal modest revenue growth to $6.90B in 2025 but declining net margins to 3.76%. Recent debt offerings of $1.5B highlight capital strategy moves amid high leverage.
Outlook remains cautiously optimistic given earnings outperformance and industry tailwinds, but risks include elevated debt levels and margin pressure. The stock offers growth potential with a 65% buy rating from analysts, though investors should weigh technical weakness against fundamental resilience in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
